use laboratory markers surrogates clinical endpoints evaluation treatment HIV infection strong ethical practical reasons decision-making efficacy new treatments human immunodeficiency virus HIV infection strategy early markers disease progression lymphocyte levels surrogates ultimate clinical endpoints development immune deficiency syndrome AIDS death evaluation new therapies simple model transitions health states alive adverse marker definitive clinical endpoint extent treatment comparisons surrogate endpoint predict ultimate clinical benefits parameters treatment HIV infection computer simulations clinical trials substantial time savings use surrogate endpoint reliance surrogate serious overestimates ultimate clinical benefit treatment delayed toxicity transient beneficial effects Likewise reliance surrogate serious underestimates ultimate clinical benefit treatment effect transition marker state rates transition marker state ultimate clinical endpoint well state ultimate clinical endpoint 